Real World Evidence: The New Standard of Proof
Increasingly, in a world where the overall impact of healthcare interventions needs to be measured practically and financially, randomised clinical trials are falling short of the evidence requirements. Debate and reflection on how pharma companies are evolving to face the new demands of real world evidence.
Locations: Paris (France), New Jersey (USA)
“Are payers and pharma aligned on the future role of Real World Evidence? How to demonstrate and communicate the better outcomes that health systems want and will pay for.”